inhibitory or stimulatory effect on cell proliferation of a number of cell types. Kar et al. (1996) described a stimulatory effect of VIP alone on hepatocytes obtained from regenerated liver of rats. 13 In addition, it has been reported that VIP may have a mitogenic effect on HT29 and H9 cell lines, 14, 15 while it can cause an inhibition of proliferation of human HepG2 cells. 16 The mitogen-activated protein kinase (MAPK) pathway has been reported to play a crucial role in hepatocyte replication. 17 Moreover, EGF-induced proliferation of rat hepatocytes is mainly dependant on the p44 and p42 isoenzymes (extracellular signal-regulated kinases, ERK1 and ERK2) of the MAPK pathway. 18 VIP stimulates intracellular production of cyclic adenosine 3′:5′-monophosphate (cAMP)
in various cell types, including hepatocytes. 8 Activation of cAMPdependant Rap1 GTPase may be associated with either activation or inhibition of the (MAPK/ERK kinase) MEK/ERK cascade. This effect relies on the presence or absence of the serine/threonine-protein kinase B-Raf, respectively in cells. 19 Of relevance is that B-Raf kinase has been detected in liver. 20 These findings support that hypothesis that VIP may contribute in hepatocytes proliferation.
In the present study, we have investigated the effects of VIP on cell proliferation, gene expression, cell signalling and function in human hepatocytes.
| MATERIAL S AND ME THODS

| Isolation of human hepatocytes
Tissue samples (2-10 g) were obtained from fresh surgical macroscopically normal liver tissue resections from patients undergoing hepa- used. Patients' ages ranged from 29 to 83 y. Hepatocytes were isolated using a 2-step perfusion procedure as described previously 21 with some modifications. Cells were plated on mouse collagen type IV gel layer 1-2.5 μg cm −2 (Corning Ltd., Flintshire, UK) in William's E medium (Thermo Fisher, Inchinnan, UK) and incubated at 37°C in a humidified incubator with 5% CO 2 .
| 5-Bromo-2′-deoxyuridine (BrdU) DNA incorporation assay
EGF (Sigma, Gillingham, UK) at 5, 10 and 20 ng mL −1 or VIP (Sigma) at 10 −8 , 10 −7 or 10 −6 M was added 24 h following cell seeding.
Hepatocytes were incubated with BrdU (10 μg ml −1 , Sigma) for 2 h at 37°C. DNA-integrated BrdU was detected by rat anti-BrdU antibody (Bio-Rad, Hertfordshire, UK) and subsequently donkey anti-rat IgG-Alexa 488 (Thermo Fisher). Nuclei were stained with 4′-6-diamidino-2-phenylindole, DAPI (Sigma). Using fluorescence microscopy, numbers of BrdU + and DAPI + cells were determined in 6 different high-power fields per well. 
| Measurement of lactate dehydrogenase (LDH) activity
| Viability and proliferation assays
Viability was determined using a colourimetric MTT assay (Sigma) and Quick Cell Proliferation Assay kit II (Abcam, Cambridge, UK)
were used according to manufacturers' instructions.
| Polymerase chain reaction and real-time PCR
RNA was extracted using a RNeasy ® kit (Qiagen, Crawley, West Sussex, UK) following the manufacturer's instructions.
Complementary DNA (cDNA) was synthesised using a Primer Reactive bands were detected using the Luminata Forte Western HRP substrate (Millipore UK Ltd., Hertfordshire, UK). In another experiment, the level of VPAC1 protein expression in untreated or VIP (10 −6 M) treated hepatocytes, was investigated using a rabbit polyclonal anti-VPAC1 (Abcam) and followed by goat anti-rabbit horseradish peroxidase (HRP) (DakoCytomation).
| cAMP direct immunoassay
Levels of cAMP in hepatocytes 24 h following cell seeding and at day 3 or 5 following stimulation with 10 −6 M VIP treatment were F I G U R E 1 Hepatocyte proliferation was stimulated by EGF or VIP. A, Representative images of hepatocytes treated with either EGF (20 ng mL −1 ) or VIP (10 -6 M) for 3 d. DNA incorporation of BrdU was determined (Green) and DAPI (Blue) was used as a nuclear counter stain. B-E, The effects of EGF or VIP were demonstrated on total and proliferating cell numbers. n = 3 different donors per condition. P values shown in the graph are for comparison to hepatocytes maintained on medium alone. *P < .05, **P < .005, ***P < .0005, ****P < .0001. Mean ± SEM. Two-way ANOVA followed by Fisher's least significant difference (LSD) detected using a cAMP direct immunoassay (Abcam) according to the manufacturer's instructions. cAMP concentrations (μM) were determined and corrected to total proteins concentrations in samples (μg).
| Albumin ELISA and Urea concentration assay
Albumin and urea concentrations in the supernatant of hepatocytes cultures were determined using the ELISA DuoSET ® kit for human albumin (R&D Systems, Oxfordshire, UK) and the QuantiChrom ™ urea assay kit (QuantiChrom, BioAssay Systems, Hayward, CA, USA)
respectively, according to the manufacturer's instructions.
| Statistics
Two-way analysis of variants (ANOVA) followed by Fisher's least significant difference (LSD) multiple comparisons tests were performed using GraphPad Prism version 7.7.1 for Windows, GraphPad
Software, La Jolla, CA, USA, www.graphpad.com. Data has been
represented by Mean ± SE of the mean (SEM) or standard deviation (SD) as indicated. P < .05 was taken as significant.
For further details regarding the materials and methods, please refer to the Data S1. Mean ± SEM. Two-way ANOVA followed by Fisher's LSD day 5 of treatment, 10 ng mL −1 (a mean of 1.5 ± SD 0.5-fold) and 20 ng mL −1 (a mean of 1.7 ± SD 0.5-fold) ( Figure 1C ). Interestingly, VIP-stimulated proliferation of human hepatocytes in a dosedependant manner at day 3 up to a mean of 3.2 ± SD 1.1-fold at 10 -6 M ( Figure 1D ). However, a decline of hepatocyte response to VIP was observed at day 5 (a mean of 1.2 ± SD 0.6-fold up to 10 -6 M) ( Figure 1E ). Similarly, EGF addition was associated with a rise in total cell numbers at day 3; 10 ng mL −1 (a mean of 1.4 ± SD 1.1-fold) and 20 ng mL −1 (a mean of 1.9 ± SD 1.7-fold) and day 5; 10 ng mL −1 (a mean of 1.7 ± SD 0.4-fold) and 20 ng mL −1 (a mean of 1.7 ± SD 0.3-fold). VIP at day 3 resulted in an increase in total cells by a mean of 2.2 ± 0.9-fold at 10 -7 M and 3.4 ± SD 1.4-fold at 10 -6 M. The drastic decrease in hepatocyte response to VIP at day 5 raised a concern about changes in cell viability and status, and was investigated further.
| RE SULTS
| VIP treatment has a limited effect on hepatocyte survival in vitro
Effects of EGF or VIP on hepatocyte integrity was tested by measuring LDH release in the cell culture supernatants. In the first 24 h following cell extraction, LDH activity was high (a mean of . n = 3. *P < .05, **P < .005. Mean ± SEM. Two-way ANOVA followed by Fisher's LSD 0.90 ± SD 0.29 U mL −1 ) (Figure 2A ), which may be a result of the isolation process or spontaneous activation of hepatocyte apoptosis. 23, 24 A dramatic decrease in LDH levels was observed in the following 24 h (a mean of 0.14 ± SD 0.16 U mL There was also a rise in LDH activity when both agents were added together to the hepatocyte culture medium (data not shown).
The metabolic activity of the cell was assessed using the MTT assay. At day 3, EGF showed a marked improvement in cell viability ( Figure 2D ) and VIP treatment was associated with a concentration dependant increase in hepatocyte metabolic activity, peaking at a concentration of 10 -6 M ( Figure 2E ). Results showed low metabolic activity of primary human hepatocytes after day 5 of cell seeding, irrespective of the addition of EGF or VIP. This result may reflect cell loss.
Previous results have shown that the support of hepatocyte survival was lacking when VIP was used alone and cells have entered a late phase of death or apoptosis. In order to address this, we have tested DMSO as an agent which may prevent this deterioration of cell viability and as reported, can maintain hepatocyte differentiation and improve liver-specific functionality. 25 DMSO alone induced cell death as compared to medium alone, however, addition of 2% DMSO to culture medium was associated with the restoration of the hepatocyte response to EGF and the VIP mitogenic effect at day 5 of treatment ( Figure 3A,B) . In addition to hepatocytes loss, the noticeable decrease in the effect of VIP by day 5 and a change in expression of VIP receptors may contribute to hepatocyte resistance VIP. To test this possibility mRNA expression of VPAC1, the most abundant VIP receptor in the liver, was investigated using a semi-quantitative RT-PCR technique. 26 In untreated hepatocytes, level of mRNA expression of VPAC1 or EGFR did not change significantly at day 3 ( Figure 3C ). However, at day 5 cells expressed lower levels of EGFR mRNA which is a phenomenon that has been reported previously 27 but VPAC1
mRNA expression did not show any change. Western blotting revealed several forms of VPAC1 in human hepatocytes at molecular weights of ~250, ~100 and ~52 kDa ( Figure 3D ), as described previously. 28 During hepatocytes culture, VPAC1 protein expression 
| Expression of proliferation-associated genes was induced by VIP treatment
Expression of the active cell cycle marker, MKI-67 29 and the mitotic marker, H3 30 genes were studied using quantitative RT-PCR.
EGF alone induced a 6-fold increase in mRNA expression of MKI-67, most significantly at day 3 of treatment at concentrations up to 10 ng mL −1 ( Figure 4A ). In addition, EGF treatment resulted in up to a 4-fold increase in expression of H3 mRNA by day 3 of treatment, most noticeably at 20 ng mL −1 EGF ( Figure 4B ). Addition of VIP to cultured hepatocytes were associated with a 2-fold increase in MKI-67 gene expression at day 3, rising to 4-fold at day 5 of treatment at a concentration of 10 -6 M ( Figure 4C ). Similarly, VIP induced a concentration-dependant increase in expression of H3 at days 3 and 5 ( Figure 4D ). Although the combination of EGF and VIP was associated with a considerable increase in expression of MKI-67 at day 5, there was no difference compared to either EGF or VIP alone ( Figure 4E ). The presence of EGF and VIP together in the culture medium had little effect on expression of H3 at day 3 ( Figure 4F ).
| Production of phospho-p44/42 MAPK (Erk1/2) in VIP treated hepatocytes
Binding of VIP to its receptors initiates cAMP production and sub- with 20 ng mL −1 EGF ( Figure 6D ). At day 3, there was an increase in albumin production up to a mean of 66.9 ± SD 76.83 ng mL −1 from hepatocytes cultured in the presence of 10 -6 M VIP ( Figure 6E ).
When both agents were added together, the stimulatory effect of EGF was inhibited ( Figure 6F ). When both agents were added sequentially, an inhibitory effect of VIP on EGF-stimulated albumin production was observed ( Figure S2 ). Urea production from hepatocytes was dramatically decreased during the 24 h following cell plating from a mean of 3.01 ± SD 0.38 mg dL −1 to a mean of 0.80 ± SD 0.98 mg dL −1 , but partial recovery was observed at day 3 and 5 (a mean of 1.26 ± SD 0.37 mg dL −1 and 1.10 ± SD 0.36 mg dL −1 respectively). EGF increased urea production on the first day of hepatocyte culture compared to untreated cells (a mean of 1.31 ± SD 0.23 mg dL −1 at 10 ng mL −1 EGF), but this effect disappeared with time ( Figure 6G ). However, 10 -7 M VIP resulted in a limited increase (a mean of 1.53 ± SD 0.51 mg dL −1 ) in urea production at day 3 as compared to control ( Figure 6H ) and adding VIP to EGF abolished the effect of EGF on urea production in cultures hepatocytes ( Figure 6I ).
| D ISCUSS I ON
Our findings have shown that EGF or VIP alone has the ability to induce DNA synthesis in cultured human hepatocytes and to supernatants of cultured hepatocytes with EGF, VIP or both were determined. n = 3 different donors per condition. P values shown in the graph are for comparison with hepatocytes at day 0 or with untreated cells. *P < .05, **P < .005, ***P < .0005, ****P < .0001. Mean ± SEM. Two-way ANOVA followed by Fisher's LSD stimulate expression of genes that may be involved in cell proliferation. Interestingly, EGF was able to maintain hepatocyte proliferation further up to day 5 whilst VIP did not. In addition, VIP was found to stimulate phosphorylation of ERK1 and 2 protein kinases. However, unlike EGF, VIP has a limited effect on hepatocyte function in vitro.
Hepatocytes move from G0 to G1 phase of cell cycle spontaneously during isolation process 32 and progress further towards and stop at a restriction point in mid-late G1 phase usually 24 and 48 h after plating. 22 Onward movement to S phase is dependent on growth factors such as EGF. 33 In agreement with that, we have demonstrated that EGF stimulated DNA synthesis when added 24 h following hepatocytes seeding. Strikingly, we observed a comparable effect with VIP which disagree to that previously reported by Kar et al. 13 The outcome of proliferative stimuli is related to the cell cycle. A few hours following isolation, VIP can facilitate entry of cells into G1 phase but it did not encourage them to pass the restriction point. 34 This effect could increase the number of cells at susceptible to the mitogenic effect of EGF. These findings might explain why VIP alone failed to stimulate DNA synthesis in hepatocytes but may potentiate the effect of EGF on cell proliferation at this early time point. 13, 22, 35 We found that VIP did activate MAPK at this early time which consistent with that has been reported. 35 The underling mechanism could involve activation of p70 ribosomal S6 protein kinase (p70S6k) activity, cyclin D3-cyclin-dependent kinase (CDK)-4 assembly or a CDK2/cyclin C-dependent inhibitory phosphorylation of the transcription factor LSF (late simian virus 40 factor) at serine 309.
36-38
As we have shown, later in culture VIP or EGF stimulated formation of pERK which has been described previously. 18, 39 This effect was found to be closely related to induction of hepatocyte proliferation 17 and may involve an MAPK-dependent reactivation phosphorylation of LSF at serine 291 which could be essential for cell cycle progression to S phase. 40 Dependence of VIP-induced ERK activation on B-Raf kinase could support our hypothesis that VIP alone is able to induce hepatocyte proliferation, but VIP exerted an inhibitory effect on EGF (Figure 7 ). In accordance with these results, it has been reported that high levels of cAMP could result in a decrease in EGF-dependent MAPK production and loss of its DNA stimulatory effect. 35 In addition, several reports have shown that cAMPdependent PKA is able to phosphorylate EGFR on serine residues which results in decrease in tyrosine kinase activity and EGFR autophosphorylation induced by EGF. 41, 42 Moreover, cAMP-GEFs can directly inhibit Raf-1 by phosphorylation at ser259 or indirectly by a PKA-dependent activation of the Raf-1 inhibitor, Akt (protein kinase B, PKB). 43, 44 This interaction could explain the reported VIP inhibitory effect on HepG2 proliferation. HepG2 survival and proliferation is depending on the presence of FBS in medium. 45, 46 VIP has been shown to inhibit HepG2 proliferation through a cAMP-dependent signal transducers and activators of transcription-3 (STAT-3) pathway inhibition, 16 the pathway that can be stimulated by growth factors which present in FBS.
The DNA synthesis in primary hepatocytes started early in culture and maximized at day 3, with expression of activated transcriptional regulators for EGF and ERK pathway, 47 but decreased afterwards even in the presence of EGF. 13, 48 Following day 3 of culture, substantial hepatocyte death has been reported and the remaining cells may become flattened and polykaryotic or smaller and apoptotic. 3 We have noticed that, at day 5 of EGF treatment, there was a lower number of living hepatocytes, and that the remaining cells replicated, but to a lower extent. This is in agreement with previous findings to that has been reported before. 33, 49 In our model, VIP did not show any change in hepatocyte proliferation, consistent with previous work. 13 Notably, the cells which proliferated under the effect of VIP mostly died by day 5 of treatment and VIP did not markedly increase DNA synthesis in the remaining cells. The lack of support of the differentiated state of hepatocytes with VIP treatment was observed from the albumin production and urea secretion at day 5, a finding that has been previously reported. 9 Interestingly, MKI-67 and H3 mRNA expression in hepatocytes showed a tendency to increase at day 5 of treatment while albumin expression decreased with time, which may be an indication of a loss of differentiation.
The dramatic change in hepatocyte response to VIP could be a consequence of changes in VIP receptors expression. We found that hepatocytes did not show such a change in expression of VPAC1 during culture time course. However, VIP failed to induce cAMP production in hepatocytes at day 5 of cell culture, which suggests an alteration of receptor signalling response. Indeed, the interaction between VIP and its receptors in proliferating hepatocytes is not completely understood. In rat liver 3 d after PH, the maximal response of VIP was reduced as a result of low number of receptors and changes in the receptor structure. 50 In addition, the decrease in VIP receptors sensitivity could be a result of high expression of VIP in proliferating liver. 13 Moreover, VPAC1 harbours several potential N-glycosylation sites which are critical for VIP binding 51 and receptor delivery to plasma membrane. 52 An alteration in N-glycosylation of proteins has been reported in dedifferentiated rat hepatocytes, 53 and could explain the decreased in VPAC1 response to VIP, but this possibility needs further investigations. In addition, we have demonstrated that addition of high concentration of VIP was associated with downregulation of VPAC1, the phenomenon that has been reported with VIP with other cell types. 54, 55 Our findings have demonstrated that VIP alone was able to induce proliferation of adult human hepatocytes when added 24 h following hepatocyte platting and this effect may be PKA/B-Raf-ERK dependent. VIP exerts an inhibitory effect on EGF signalling pathway at this time point of cell cycle. Stimulation of the VIP pathway may aid hepatocyte proliferation in vitro.
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